Navigation Links
Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
Date:3/29/2008

NATICK, Mass. and CHICAGO, March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of two-year data from more than 7,000 patients in the TAXUS ARRIVE Registry program. The study was designed to evaluate the safety performance of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System in patients treated in "real-world" practice. Outcomes through two years in the simple- use (single vessel/stent) patient group confirmed the favorable results seen in similar patients enrolled in previous TAXUS randomized clinical trials (the clinical trial cohort). Results in the more complex expanded-use group also continued the expected slightly higher event rates than simple-use patients, but were still favorable through two years compared to the published outcomes of other treatment modalities for such patients. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago.

"The extensive ARRIVE data show favorable and consistent outcomes in high- risk groups representing some of the most complex patients and lesions," said Dr. Lasala, Professor of Medicine, Washington University School of Medicine in St. Louis. "Outcomes in the simple-use patients in ARRIVE are consistent with results from the TAXUS Stent cohorts in the TAXUS randomized clinical trial program, indicating that the ARRIVE methodology is very efficient in capturing adverse event outcomes. Overall, then, these results support the long-term performance of the TAXUS Stent across the broad range of patients studied in these trials and registries."

The pooled analysis included two-year outcomes for 7,033 patients in t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)
4. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
7. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
8. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
9. Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007
10. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
11. Patient-Reported Outcomes (PROs) Improve Cancer Treatment -- Experts Agree
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Inc., a developer of innovative therapeutics for diseases ... results for the company,s lead product candidate, OTO-104, ... demonstrated that a single intratympanic (IT) injection of ... corticosteroid dexamethasone, provided significant protection against both noise-induced ...
... Feb. 22, 2011 Jennerex, Inc. (San ... appointment of James M. Burke, M.D. to the newly-created ... be responsible for all global clinical research activities related ... has been working with Jennerex in an advisory capacity ...
... KONG, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... first and largest cord blood banking operator in China, today ... was held on February 18, 2011, in Hong Kong. ... Albert Chen and Mark Chen to serve on the Board ...
Cached Biology Technology:Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 3Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research 2China Cord Blood Corporation Announces Results of 2010 Annual General Meeting 2
(Date:7/9/2014)... on the verge of an economy driven by methane, the ... and is undergoing a production boom. It has poised the ... is casting serious doubts over just how climate-friendly it is, ... (C&EN), the weekly news magazine of the American Chemical ... at C&EN, explains that when burned as a fuel to ...
(Date:7/9/2014)... Can thyroid hormone protect neuronal function and increase ... Ailing Fu and her team, School of Pharmaceutical ... in which aged mice were administered with low ... showed that the aged rats exhibited an obvious ... rate from 60% to 93%. The underlying mechanism ...
(Date:7/9/2014)... They are amongst the most numerous inhabitants of the ... . Not visible to the naked eye, when they ... sized patches, they are even visible on satellite images. ... responsible for approximately half of the global photosynthesis output," ... University Jena (Germany). In the process the greenhouse gas ...
Breaking Biology News(10 mins):Short circuit in the food web 2
... of scientists, including University of Colorado School of Medicine ... disease related to an inability to process Vitamin B12. ... "Some people with rare inherited conditions cannot process vitamin ... a geneticist and senior author of a paper about ...
... key role in preserving biological diversity. A new study carried ... (SLU), among others, indicates that if the world,s religious leaders ... positioned to do so. Our study investigates how ... they overlap areas that are important for global biological diversity, ...
... $4.5 million over the next five years for a ... detecting disorders and conditions can and should become a ... one of four projects launched today by the National ... providing genetic sequencing as part of, or instead of, ...
Cached Biology News:Peering into genetic defects, CU scientists discover a new metabolic disease 2Peering into genetic defects, CU scientists discover a new metabolic disease 3Religious leaders can be key to biological diversity 2UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4
... The APO-BRDU Kit is a two ... and total cellular DNA to detect apoptotic ... the instructions and reagents required for measuring ... control cells for assessing reagent performance; washing, ...
... CHEMICON APO-BRDU Kit is a ... breaks and total cellular DNA to detect ... kit contains the instructions and reagents required ... and negative control cells for assessing reagent ...
... with temperature probe, 100-120 and 220-240 V, supports ... and 400 W. The temperature probe is used ... degrees C during electrophoresis. Built-in infrared capability allows ... are provided. Dimensions are 27.5 x 34 x ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: